Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2025)

Historic Capital Leases for Vanda Pharmaceuticals (VNDA) over the last 2 years, with Q4 2025 value amounting to $4.1 million.

  • Vanda Pharmaceuticals' Capital Leases rose 2956.13% to $4.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.1 million, marking a year-over-year increase of 2956.13%. This contributed to the annual value of $4.1 million for FY2025, which is 2956.13% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Capital Leases of $4.1 million as of Q4 2025, which was up 2956.13% from $2.8 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Capital Leases ranged from a high of $4.1 million in Q4 2025 and a low of $2.8 million during Q3 2025